### Calcium Channel Blockers Treatment Selector

**Charts reviewed June 2022. Full information available at www.hiv-druginteractions.org**

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

<table>
<thead>
<tr>
<th>Calcium Channel Blockers</th>
<th>AT/VP</th>
<th>ATV/r</th>
<th>DRV/c</th>
<th>DRV/r</th>
<th>LPV/r</th>
<th>DOR</th>
<th>EFV</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>RPV oral</th>
<th>FTR</th>
<th>MVC</th>
<th>BIC/ FTA</th>
<th>CAB oral</th>
<th>CAB/ RPV</th>
<th>DTG</th>
<th>EVG/c</th>
<th>EVG/c</th>
<th>F/TAF</th>
<th>FTC</th>
<th>FTC</th>
<th>TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Felodipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Lacidipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Lercanidipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Nicardipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Nilnidipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Nisoldipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Verapamil</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
</tbody>
</table>

#### Interactions with CAB/RPV long acting injections

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

Interactions with Ibalizumab

None

### Colour Legend

- [ ] No clinically significant interaction expected.
- [ ] These drugs should not be coadministered.
- [ ] Potential interaction which may require a dose adjustment or close monitoring.
- [ ] Potential interaction predicted to be of weak intensity.
- [ ] No prior dosage adjustment is recommended.

### Text Legend

↑ Potential increased exposure of the antihypertensive
↓ Potential decreased exposure of the antihypertensive
⇔ No significant effect
♥ One or both drugs may cause QT and/or PR prolongation.

ECG monitoring is advised if coadministered with atazanavir or lopinavir.

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

**Notes**

a. Coadministration may increase bicitgravir concentrations; no effect on emtricitabine or tenofovir alafenamide is expected.

b. Coadministration may increase bicitgravir and tenofovir alafenamide concentrations; no effect on emtricitabine is expected.

c. Coadministration could potentially increase the absorption of tenofovir alafenamide, thereby increasing the systemic concentration of tenofovir.

d. Coadministration could potentially increase the absorption of tenofovir-OF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Dunca Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.